Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
Arissa Young, Henry T. Quach, Haocan Song, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e000821-e000821
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Immune-checkpoint inhibitors: long-term implications of toxicity
Douglas B. Johnson, Caroline A. Nebhan, Javid J. Moslehi, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 4, pp. 254-267
Open Access | Times Cited: 652
Harnessing big data to characterize immune-related adverse events
Ying Jing, Jingwen Yang, Douglas B. Johnson, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 4, pp. 269-280
Closed Access | Times Cited: 79
Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
Silvia Casagrande, Giulia Boscato Sopetto, Giovanni Bertalot, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1440-1440
Open Access | Times Cited: 19
Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta‐analysis
Yukinori Takenaka, Ryohei Oya, Norihiko Takemoto, et al.
Journal of Cachexia Sarcopenia and Muscle (2021) Vol. 12, Iss. 5, pp. 1122-1135
Open Access | Times Cited: 88
Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications
Jacqueline Vuong, Ashley Stein-Merlob, Arash Nayeri, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 6, pp. 577-593
Open Access | Times Cited: 59
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study
Ji Hyun Lee, Sujin Hyung, Jeeyun Lee, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 8, pp. e005226-e005226
Open Access | Times Cited: 48
Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma
Bang‐Bin Chen, Po‐Chin Liang, Tiffany Ting‐Fang Shih, et al.
European Radiology (2022) Vol. 33, Iss. 1, pp. 512-522
Closed Access | Times Cited: 44
Adiposity and cancer survival: a systematic review and meta-analysis
En Cheng, Jocelyn Kirley, Elizabeth M. Cespedes Feliciano, et al.
Cancer Causes & Control (2022) Vol. 33, Iss. 10, pp. 1219-1246
Open Access | Times Cited: 38
Obesity and immune-checkpoint inhibitors in advanced melanoma: A meta-analysis of survival outcomes from clinical studies
Gabriele Roccuzzo, Giovenale Moirano, Paolo Fava, et al.
Seminars in Cancer Biology (2023) Vol. 91, pp. 27-34
Closed Access | Times Cited: 33
Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Shuluan Li, Tianyu Wang, Gangling Tong, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 41
Association Between Visceral Fat Area and Cancer Prognosis: A Population-Based Multicenter Prospective Study
Lingyu Li, Wenqian Li, Dongsheng Xu, et al.
American Journal of Clinical Nutrition (2023) Vol. 118, Iss. 3, pp. 507-517
Open Access | Times Cited: 20
Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy – A systematic review and meta-analysis
Paul Trinkner, Sophie Günther, Ina Monsef, et al.
European Journal of Cancer (2023) Vol. 184, pp. 151-171
Closed Access | Times Cited: 19
Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction
Ruixia Song, Fengsen Liu, Yu Ping, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 19
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Selina K. Wong, Caroline A. Nebhan, Douglas B. Johnson
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 40
Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer
Meytal Guller, Matthew E. Herberg, Neha Amin, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5772-5772
Open Access | Times Cited: 38
Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review
Alice Indini, Erika Rijavec, Michele Ghidini, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2628-2628
Open Access | Times Cited: 34
Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle
S. Antoun, Émilie Lanoy, Samy Ammari, et al.
European Journal of Cancer (2022) Vol. 178, pp. 49-59
Open Access | Times Cited: 26
Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study
Lushan Xiao, Rui-ning Li, Hao Cui, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 24
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
Dylan J. Martini, T. Anders Olsen, Subir Goyal, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 31
Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review
Laurens S. ter Maat, Isabella A.J. van Duin, Sjoerd G. Elias, et al.
European Journal of Cancer (2022) Vol. 175, pp. 60-76
Open Access | Times Cited: 19
The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms
Andrew W. Hahn, Neha Venkatesh, Pavlos Msaouel, et al.
Cells (2023) Vol. 12, Iss. 21, pp. 2551-2551
Open Access | Times Cited: 11
Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall
Linda Piras, Michela Zuccanti, Paola Russo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2502-2502
Open Access | Times Cited: 4
Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Nina Glassée, Michal Kiciński, et al.
EJC Skin Cancer (2025), pp. 100284-100284
Open Access
Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events
James W. Smithy, David Faleck, Michael A. Postow
Clinical Cancer Research (2021) Vol. 28, Iss. 7, pp. 1250-1257
Open Access | Times Cited: 26
Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study
Hideto Ueki, Takuto Hara, Yasuyoshi Okamura, et al.
Investigative and Clinical Urology (2022) Vol. 63, Iss. 4, pp. 415-415
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top